CN Patent

CN101861313B — 苯基氨基嘧啶化合物及其用途

Assigned to Sierra Oncology Co ltd · Expires 2014-06-04 · 12y expired

What this patent protects

本发明涉及苯基氨基嘧啶化合物，其为蛋白激酶(包括JAK激酶)的抑制剂。特别地，所述化合物对JAK2激酶具有选择性。所述激酶抑制剂可被用于治疗激酶相关性疾病，例如免疫性疾病和炎性疾病(包括器官移植)；过度增殖性疾病(包括癌症和骨髓增殖性疾病)；病毒性疾病；代谢性疾病；以及血管疾病。

USPTO Abstract

本发明涉及苯基氨基嘧啶化合物，其为蛋白激酶(包括JAK激酶)的抑制剂。特别地，所述化合物对JAK2激酶具有选择性。所述激酶抑制剂可被用于治疗激酶相关性疾病，例如免疫性疾病和炎性疾病(包括器官移植)；过度增殖性疾病(包括癌症和骨髓增殖性疾病)；病毒性疾病；代谢性疾病；以及血管疾病。

Drugs covered by this patent

momelotinib-dihydrochloride (MOMELOTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN101861313B
Jurisdiction: CN
Classification: —
Expires: 2014-06-04
Drug substance claim: No
Drug product claim: No
Assignee: Sierra Oncology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.